期刊文献+

糖尿病高危人群脂肪细胞因子与代谢综合征关系的研究 被引量:15

Relationship between metabolic syndrome and adipokines on diabetes among high-risk populations
原文传递
导出
摘要 目的研究脂肪细胞因子与代谢综合征(MS)的关系,探讨其对MS临床诊断的预测价值。方法收集414名2型糖尿病(T2DM)一级亲属,根据2005年国际糖尿病联盟(IDF)共识诊断MS标准,分为MS。组(无MS组分)115例,MS1组(1种MS组分)118例,MS2组(2种MS组分)77例,MS3组(≥3种MS组分)104例,酶联免疫法测定上述人群的瘦素、内脂素、脂联素及抵抗素水平,放射免疫法测定血清视黄醇结合蛋白-4(RBP-4)。结果(1)随MS组分个数的聚集,血清脂联索水平逐渐降低,瘦素及女性RBP-4水平逐渐增加,三者均与MS组分聚集有较强的平行关系;而内脂素水平只在MS,组有明显降低;抵抗素水平则未见随MS组分聚集有变化趋势。(2)高瘦素水平Q4组(以四分位值分组)与低瘦素水平Q1组比较,MS的各组分(高血压、高血糖、血脂异常、胰岛素抵抗和肥胖)的检出率明显增加(Q4/Q1的OR值分别为1.3、1.8、1.6、5.2和3.0)。(3)血清RBP-4水平增加不仅与糖调节异常相关(Q4/Q1,OR=2.6),且与高血压(Q4/Q1,OR=1.6)、血脂异常(Q4/QI,OR=1.9)和肥胖(Q4/Q1,OR=1.5)及聚集即MS更相关(Q4/Q1,OR=2.7)。在RBP-4水平高的Q4组,MS检出率为50%。(4)处于脂联素水平最低的Q1组与最高的Q4组相比,MS及其组分(血脂异常、肥胖、高血糖和胰岛素抵抗)的检出率显著增加(Q4/Q1,OR值为2.1—4.1),但高血压的检出率却呈下降趋势。结论脂肪因子中以脂联素、瘦素和RBP-4与MS的关系最密切。提示三者可能也是参与MS形成的关键因子,可作为MS发病的早期预示标志物和治疗新靶点。 Objective To study the relationship between adipokines and metabolic syndrome (MS), and the predictive value of adipokines on diagnosis of MS. Methods According to the IDF consensus worldwide definition on MS in 2005, we divided the subjects into 4 groups: 115 in MS0 (with none of MS component) ; 118 in MS1 (with one MS component) ; 77 in MS2 (with two MS components) and 104 in MS3 (with none of MS component). Serum levels of leptin, visfatin adiponectin and resistin were measured in these groups, using the enzymelinked immunosorbent assay (ELISA) method. Retinol-binding protein 4 (RBP-4) was assessed by radioimmunoassay (RIA). Result ( 1 ) Serum adiponectin level decreased while the serum level of leptin and RBP-4 increased in women with the number of MS components gathered. However, the level of visfatin obviously decreased only in the MS3 phase. The level of resistin showed no changes with MS components gathered. (2) Detection rates of the MS components such as high blood pressure, hyperglycemia,dyslipidemia, insulin resistance and obesity were significantly higher in the Q4 group with high level of leptin when compared to the Q1 group with lower level (odd ratio: Q4/Q1 is 1.3,1.8,1.6,5.2,3.0 respectively). (3) The higher level of serum RBP-4 was not only associated with greater risk for impaired glucose regulation (odd ratio: Q4/Q1=2.6) , but also significantly with the risks for hyperglycemia (odd ratio: Q4/Q1 = 1.6) dyslipidemia (odd ratio: Q4/Q1 = 1.9), obesity(odd ratio: Q4/ Q 1= 1.5 ) and MS (odd ratio: Q4/Q 1 = 2.7). In the Q4 group with higher levels of RBP-4, the positive rates of MS reached 50%. (4) The detection rates of MS components such as dyslipidemia, obesity, hyperglycemia, and insulin resistance were significantly higher in the Q1 group with the lowest level of adiponeptin when compared to the Q4 group with the highest level. Conclusion The levels of adipokines, serum adiponectin, leptin and RBP-4 showed sig
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2012年第4期418-422,共5页 Chinese Journal of Epidemiology
基金 基金项目:北京市科技新星计~(2004A27) 首都医学发展基金(ZD2002-3034)
关键词 代谢综合征 瘦素 内脂素 脂联素 抵抗素 视黄醇结合蛋白-4 Metabolic syndrome Lepfin Visfatin Adiponectin Resistin Retinol binding protein-4
  • 相关文献

参考文献17

  • 1Hutley L,Prins JB. Fat as endocrine organ: relationship to the metabolic syndromel. Am J Med Sci, 2005,330 (6) : 2802-2891. 被引量:1
  • 2Susan EW, Laura LG, Mitchell SW. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci, 2009, 54 (9) : 1847-1857. 被引量:1
  • 3宋秀霞 ,纪立农 .国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志(1006-6187),2005,13(3):178-180. 被引量:611
  • 4Alberti KG, Zimmet P, Shaw J. Metabolic syndrome -- a new world wide definition. A Consensus Statement from the InternationalDiabetes Federation. Diabet Med, 2005,23 (5) : 469-480. 被引量:1
  • 5Appel S J, Jones ED, Kennedy-Malone L. Central obesity and the metabolic syndrome: implications for primary care providers. J Am Acad Nurse Pract, 2004,16 (8) : 335-342. 被引量:1
  • 6吴静,王宏伟,温宇.新型脂肪因子visfatin的生物学意义[J].生理科学进展,2006,37(4):353-355. 被引量:4
  • 7Trayhum P, Beattie JH. Physiological role of adipose tissue as an endocrine and secretory organ. Proc Nutr Soc, 2001,60 (3) : 329-339. 被引量:1
  • 8Kusminski CM, Scherer PE. The road from discovery to clinic: a diponectin as a biomarker of metabolic status. Clin Pharmacol Ther, 2009,86 (6) : 592-595. 被引量:1
  • 9Qi Q, Yu z, Ye x, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab, 2007,92 (12) : 4827-4834. 被引量:1
  • 10Choi KM, Yarmakoulia M, Park MS, et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr, 2011,93 ( 1 ) : 19-26. 被引量:1

二级参考文献32

  • 1Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med,2003,4(suppl 6):s11-s18. 被引量:1
  • 2Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol,1994,73:460-468. 被引量:1
  • 3Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med,2003,115(suppl 8A):24s-28s. 被引量:1
  • 4Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care,2003,26:1513-1517. 被引量:1
  • 5Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes,2001,109:s548-559. 被引量:1
  • 6Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001,285:1585-1591. 被引量:1
  • 7Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004,27:1182-1186. 被引量:1
  • 8Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003,26:3230-3236. 被引量:1
  • 9Tuomilehto J, Lindstrm J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM, 2001,344:1343-1350. 被引量:1
  • 10Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet,2003,361:2005-2016. 被引量:1

共引文献612

同被引文献188

引证文献15

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部